Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × liposomal doxorubicin × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 11 Fallopian Tube Neoplasms 7 Breast Neoplasms 5 Triple Negative Breast Neoplasms 3 Sarcoma, Kaposi 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Neoplasm Metastasis 2 Multi-centric Castleman's Disease 2 Carcinoma, Ovarian Epithelial 2 Acquired Immunodeficiency Syndrome 2 Vaccinia 1 Sarcoma, Ewing 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Macular dystrophy, corneal type 1 1 Lymphoproliferative Disorders 1 Lymphoma, Follicular 1 Lymphoma 1 Lymphadenopathy 1 Low Grade Serous Ovarian Cancer 1 Leiomyosarcoma 1 Hodgkin Disease 1 HIV Infections 1 AIDS-related Kaposi sarcoma 1

Interventions

Cyclophosphamide 25 Rituximab 20 fludarabine 17 Prednisone 14 Biopsy 14 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Doxorubicin 9 Vincristine 8 Lenalidomide 8 Bendamustine Hydrochloride 8 venetoclax 7 pembrolizumab 7 obinutuzumab 7 fludarabine phosphate 6 Etoposide 6 Mycophenolic Acid 5 Mesna 5 Melphalan 5 Gemcitabine 5 Cytarabine 5 zanubrutinib 4 Whole-Body Irradiation 4 Tacrolimus 4 Sirolimus 4 Oxaliplatin 4 trametinib 3 polatuzumab vedotin 3 glofitamab 3 copanlisib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06425302 2026-01-08

GOLSEEK-2

Celgene

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡